The global liquid biopsy market was valued at USD 7.25 billion in 2025. The market is projected to grow from USD 8.65 billion in 2026 to USD 26.25 billion by 2034, exhibiting a compound annual growth rate of 14.89% during the forecast period. Contrive Datum Insights presents this information in its report titled "Liquid Biopsy Market Size, Share & Industry Analysis, By Biomarker (Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins), Technology (Multi-gene-parallel Analysis (NGS), Single Gene Analysis (PCR Microarrays)), Application (Diagnosis & Companion Diagnostics, Treatment Selection & Monitoring, Recurrence/MRD Monitoring, Early Cancer Screening), End user (Reference/Central Laboratories, Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), Sample type (Blood-based (Plasma/Serum), Urine-based, Other Biofluids (CSF, Pleural Fluid, Saliva)), and Regional Forecast, 2026-2034".
Liquid biopsy testing analyzes circulating tumor material such as cell-free nucleic acids, whole tumor cells, exosomes, or tumor-derived proteins drawn from blood or another body fluid, rather than from a surgical tissue sample. Oncologists order these tests to select or adjust cancer treatment, to check for early disease recurrence, and increasingly to screen for cancer before symptoms appear. Buyers span hospital and reference laboratories that run the assays, pharmaceutical companies that use them to select clinical trial patients, and the diagnostic manufacturers and specialty labs that develop and sell the underlying tests.
Expansion of companion-diagnostic approvals built on ctDNA assays
Expansion of companion-diagnostic approvals built on ctDNA assays is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 14.89% a year, the biomarker lines exposed to it move fastest: Exosomes/Microvesicles compounds at 17.7%, taking its share of revenue from 12% to 15.01% and its value from USD 0.87 billion to USD 3.94 billion.
The study also runs a bull case: the bull case assumes companion-diagnostic and MRD reimbursement broadens faster than its recent pace, and at least one multi-cancer screening test gains and holds broad payer coverage. That path ends 2034 at USD 30.19 billion, above the USD 26.25 billion base case.
On the downside, the bear case assumes reimbursement for screening and recurrence-monitoring indications stalls near its current scope, and panel pricing declines more slowly than the base case assumes, which would hold 2034 revenue to USD 22.31 billion. CTC, which carries 22.07% of 2025 revenue, already grows at only 10.8% against the market's 14.89%, so the largest part of the base is also its slowest.
Key Players Compete on Circulating Nucleic Acids Volume and Exosomes/Microvesicles Growth
The biomarker axis, not the regional one, is what divides the field. Circulating Nucleic Acids is the volume position, 58.07% of 2025 revenue at USD 4.21 billion, holding 62.02% through 2034, and it is defended by scale. Exosomes/Microvesicles is the growth position at 17.7%, and it is open. Strength in one does not carry into the other.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Technology | Multi-gene-parallel Analysis (NGS) | 68% · USD 4.93 billion | — |
| Application | Diagnosis & Companion Diagnostics | 40% · USD 2.9 billion | Early Cancer Screening 19.91% |
| End user | Reference/Central Laboratories | 38.07% · USD 2.76 billion | Pharmaceutical & Biotechnology Companies 17.18% |
| Sample type | Blood-based (Plasma/Serum) | 88% · USD 6.38 billion | Urine-based 18.57% |
- Based on regional analysis, North America led the global liquid biopsy market in 2025 with 42.07% of global revenue at USD 3.05 billion, reaching USD 9.98 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22.07% in 2025 to 27.01% in 2034, with revenue growing from USD 1.6 billion to USD 7.09 billion.
- At 3.86% of 2025 revenue and 4.5% by 2034, Middle East and Africa is the smallest region throughout.
- Circulating Nucleic Acids was the leading biomarker line in 2025, taking 58.07% of revenue at USD 4.21 billion.
- No biomarker line grows faster than Exosomes/Microvesicles, at a projected 17.7%.
- The United States is the largest single country market at USD 2.75 billion in 2025, 37.93% of global revenue.
Coverage runs to five axes, by biomarker, and by technology, application, end user and sample type, with a revenue figure and a growth rate for every line in every year from 2020 to 2034, and bear, base and bull cases on the headline total at USD 22.31 billion and USD 30.19 billion by 2034. All five regions are broken out to country level, alongside the competitive landscape and the methodology behind each estimate. The study is delivered as a PDF, and a free sample can be requested.